123

CENTENNIAL, Colo., June 6, 2011—Cell>Point announced today that it will present Phase 2 clinical trial results for its cancer molecular imaging agent, 99mTc-EC-G

http://www.cellpointweb.com/2011-SNM-Final.pdf